Akari Therapeutics (AKTX) Liabilities and Shareholders Equity (2011 - 2026)
Akari Therapeutics recorded quarterly Liabilities and Shareholders Equity of $33.9 million in Q1 2026, down 29.24% quarter-over-quarter from $47.9 million in Q4 2025, and down 33.5% year-over-year from $51.0 million in Q1 2025.
Akari Therapeutics' Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $33.9 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 33.5% year-over-year to $33.9 million; the TTM figure through Mar 2026 stood at $178.1 million (up 62.87% YoY), while the FY2025 annual figure was $47.9 million, down 5.28% from the prior year.
- Liabilities and Shareholders Equity came in at $33.9 million for Q1 2026 at Akari Therapeutics, down from $47.9 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $51.0 million in Q1 2025 to a low of $2.7 million in Q3 2024.
- A 5-year average of $24.8 million and a median of $16.6 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity sank 99.96% in 2022 and surged 1738.35% in 2025, its largest moves.
- Akari Therapeutics' Liabilities and Shareholders Equity stood at $13.8 million in 2022, then sank by 68.52% to $4.4 million in 2023, then surged by 1061.01% to $50.6 million in 2024, then fell by 5.28% to $47.9 million in 2025, then decreased by 29.24% to $33.9 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $33.9 million, $47.9 million, and $45.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 2.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.89 Mn |
| Dec 31, 2025 | 47.89 Mn |
| Sep 30, 2025 | 45.38 Mn |
| Jun 30, 2025 | 50.91 Mn |
| Mar 31, 2025 | 50.96 Mn |
| Dec 31, 2024 | 50.56 Mn |
| Sep 30, 2024 | 2.73 Mn |
| Jun 30, 2024 | 5.08 Mn |
| Mar 31, 2024 | 2.77 Mn |
| Dec 31, 2023 | 4.36 Mn |
| Jun 30, 2023 | 8.01 Mn |
| Dec 31, 2022 | 13.83 Mn |
| Jun 30, 2022 | 11.37 Mn |
| Mar 31, 2022 | 19.45 Mn |
| Dec 31, 2021 | 38.48 Bn |
| Sep 30, 2021 | 14.72 Mn |
| Jun 30, 2021 | 4.83 Mn |
| Mar 31, 2021 | 7.84 Mn |
| Dec 31, 2020 | 41,754.00 |
| Sep 30, 2020 | 13.69 Mn |
| Jun 30, 2020 | 14.45 Mn |
| Mar 31, 2020 | 9.68 Mn |
| Dec 31, 2019 | 34,212.00 |
| Sep 30, 2019 | 10.27 Mn |
| Jun 30, 2019 | 4.61 Mn |
| Mar 31, 2019 | 8.23 Mn |
| Dec 31, 2018 | 40.73 Bn |
| Sep 30, 2018 | 12.63 Mn |
| Jun 30, 2018 | 17.12 Mn |
| Mar 31, 2018 | 25.50 Mn |
| Dec 31, 2017 | 61.92 Bn |
| Sep 30, 2017 | 22.43 Mn |
| Jun 30, 2017 | 32.05 Mn |
| Mar 31, 2017 | 36.52 Mn |
| Dec 31, 2016 | 70.12 Bn |
| Sep 30, 2016 | 52.07 Mn |
| Jun 30, 2016 | 57.63 Mn |
| Mar 31, 2016 | 62.96 Mn |
| Dec 31, 2015 | 93.40 Bn |
| Sep 30, 2015 | 79.17 Mn |
| Jun 30, 2015 | 2.96 Mn |
| Mar 31, 2015 | 4.32 Mn |
| Dec 31, 2014 | 3.39 Mn |
| Dec 31, 2013 | 7.83 Mn |
| Dec 31, 2012 | 1.12 Mn |
| Dec 31, 2011 | 27,000.00 |